Clinical trials: Non Alcoholic Fatty Liver
PreDiabetes, NAFLD
Effects of Almonds in Glucose-intolerant Adults (AGAMEMNON)
Tree nuts - such as almonds - contribute to beneficial effects of the Mediterranean diet on risk for cardiovascular events, type 2 diabetes, dyslipidemia, hypertension, inflammation and non-alcoholic fatty liver disease.
- Trial name
- AGAMEMNON (NCT06413069)
- Testing
- Raw whole almonds
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Charite University, Berlin, Germany
NAFLD
Polyunsaturated Fatty Acids in Patients With NAFLD.
Patients with metabolic syndrome and Nonalcoholic fatty liver disease (NAFLD) will be randomly allocated for the treatment with n-3 PUFA (3.6 g/day) or placebo for 12 months.
- Trial name
- NCT02647294
- Testing
- Maxicor
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- General University Hospital, Prague
Non-Alcoholic Fatty Liver Disease, Steatosis of Liver
Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED
Hepatic steatosis is a common radiographic "incidental finding" that is overlooked and underreported to patients. The investigators developed a clinical decision support system using machine learning and natural language…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Steatosis of Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease
- Trial name
- STIRRED (NCT06944353)
- Testing
- STIRRED
- Where
- United States
- Volunteers
- 4,704 people
- Sponsor
- Northwestern University
Liver Disease
Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis
Non-alcoholic steatohepatitis represents 10 - 15% total cases of hepatic cirrhosis. In the upcoming years, the economic burden of this disease will increase and will mean an important problem for our health system due to obesity…
- Trial name
- NCT01650181
- Testing
- Metformin, Siliphos+ Selenium - Methionine + Alpha Lipoic Acid
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Chronic HCV Infection, Nonalcoholic Steatohepatitis
Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection
In the presented project, the role of heme oxygenase 1 and 2 in the procesess associated with fibroproduction in the chronic HCV infection will be studied.
- Trial name
- NCT00842205
- Testing
- pegylated interferon, Ribavarin
- Where
- Czechia
- Volunteers
- 150 people
- Sponsor
- Charles University, Czech Republic
NAFLD, Type 2 Diabetes
Postprandial VLDL-triglyceride Metabolism in Type 2 Diabetes Patients With and Without NAFLD
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from simple reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH).
- Trial name
- NCT05044130
- Testing
- High-fat mixed-meal tolerance test (HF-MMTT)
- Where
- Denmark
- Volunteers
- 17 people
- Sponsor
- University of Aarhus
Non-alcoholic Steatohepatitis
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis
The aim of the present study was to compare the effects of simvastatin and L-carnitine coadministration versus simvastatin, L-Carnitine monotherapy on liver transaminases and liver elasticity in NASH patients.
- Trial name
- NALCAT (NCT01617772)
- Testing
- Atorvastatin, L-Carnitine
- Where
- 2 sites in Iran
- Volunteers
- 440 people
- Sponsor
- Tehran University of Medical Sciences
Steatohepatitis, Nonalcoholic
Screening for Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) at Al-Rajhy Hospital Nutrition Clinic. Assiut, Egypt
Primary outcome Screen for MAFLD among patients attending to the Nutrition clinic in Al Rajhi hospital. Secondary outcome Determining the degrees of fibrosis and steatosis in patients with MAFLD Determining the rate of obesity…
- Trial name
- NCT04861012
- Testing
- Ultrasound
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Assiut University
Obesity, Weight Loss
Weight Loss in Adults With Obesity Using a Combination of Low Energy Diet, Group Treatment and Intragastric Balloon
In Sweden, approximately 1.3 million adults have obesity. Obesity decreases quality of life (QoL) and increases the risk of diseases such as type 2-diabetes, non-alcoholic fatty liver disease (NAFLD), cancer and cardiovascular…
- Conditions
- Obesity, Weight Loss, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT04230655
- Testing
- Low energy diet using meal replacements, CBT-based group treatment, Intragastric balloon
- Where
- Sweden
- Volunteers
- 110 people
- Sponsor
- Region Örebro County
Non-alcoholic Fatty Liver Disease, Obesity
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
This study is open to adults with overweight or obesity who also have fatty liver disease. The purpose of this study is to find the highest dose of BI 3006337 that people with overweight or obesity and with fatty liver disease…
- Trial name
- NCT05970640
- Testing
- BI 3006337
- Where
- 12 sites in United States
- Volunteers
- 64 people
- Sponsor
- Boehringer Ingelheim
Hyperoxaluria, Nonalcoholic Fatty Liver Disease
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
The purpose of this study is to test the safety of BMN 255 and to learn about the effect BMN 255 has on you and your hyperoxaluria associated with NAFLD, and compare these effects with a placebo.
- Conditions
- Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
- Trial name
- NCT06138327
- Testing
- BMN 255
- Where
- 7 sites in United States
- Sponsor
- BioMarin Pharmaceutical
Non-alcoholic Fatty Liver Disease (NAFLD)
NASH Patient's Itinerary: Comparison of Strategies for Screening, Referring and Management of Diabetic Patients
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, underdiagnosed, health system burden and impacts on quality of life including comorbidities in the affected population.
- Trial name
- NASH-PI (NCT06688149)
- Testing
- Derivation algorithms
- Where
- 4 sites in Germany, Greece and 1 more
- Volunteers
- 536 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Non-alcoholic Fatty Liver Disease
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic…
- Trial name
- NCT07358546
- Testing
- Efimosfermin alfa
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Non-Alcoholic Fatty Liver Disease
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
The purpose of this study is to create a resource that will advance research that is focused on discovery of novel therapies, risk stratification, and aggressive interventions for those at highest risk for non-alcoholic fatty…
- Trial name
- AVAIL (NCT04807868)
- Testing
- Standard of care liver biopsy, Fibroscan, Biospecimen Collection
- Where
- United States
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Liver Diseases
Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions
Non-alcoholic fatty liver disease is the most common cause of chronic liver disease worldwide. It is defined as the accumulation of fat (>5%) in the liver cells in the absence of excessive alcohol intake or other causes of liver…
- Trial name
- NCT03172650
- Testing
- glomerular filtration rate
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Assiut University
Non-Alcoholic Fatty Liver Disease
The Effect of Coenzyme Q10 on Endothelial, Vascular and Myocardial Function
Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk. The aim of this study is to investigate the effects of coenzyme Q10 (CoQ10) on endothelial, vascular and myocardial function in patients…
- Trial name
- NCT05941910
- Testing
- Q10
- Where
- Greece
- Volunteers
- 60 people
- Sponsor
- Attikon Hospital
Non-alcoholic Steatohepatitis
The Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of HEC88473 in Healthy Subjects
A Phase 1, double blind, placebo controlled, single and multiple ascending dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study of HEC88473 in healthy subjects
- Trial name
- NCT04829123
- Testing
- HEC88473 injection
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.
Non-Alcoholic Fatty Liver Disease, Liver Disease; Alcohol-Related
FibroScan-Reproducibility and Repeatability Study
Chronic liver disease (CLD) is a serious health issue worldwide, often progressing without symptoms until advanced stages with risks of complications like liver cancer and cirrhosis.
- Trial name
- FibroScan-RR (NCT06877026)
- Testing
- FibroScan, Liver Enzymes
- Where
- United Kingdom
- Volunteers
- 108 people
- Sponsor
- Echosens
Non-Alcoholic Fatty Liver Disease, Liver Diseases
Treating Pediatric NAFLD with Nutrition
This is a proof of concept clinical trial to compare daily intake of at least 20 grams of whole dairy fat vs habitual diet on hepatic steatosis in children with NAFLD.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Diseases, Liver Fat, Hepatic Steatosis
- Trial name
- NCT05499585
- Testing
- Whole Dairy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Diego
NASH, NAFLD
Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With NASH/NAFLD
This is a Phase Ib/II, randomized, double-blind, placebo-controlled, international multi-center clinical study to investigate the efficacy and safety of GH509 in subjects with NASH/NAFLD
- Trial name
- NCT05784779
- Testing
- GH509
- Where
- China
- Volunteers
- 180 people
- Sponsor
- 1Globe Biomedical Co., Ltd.